Reduction of transplant arteriosclerosis after treatment with mycophenolate mofetil and ganciclovir in a mouse aortic allograft model

Experimental and Clinical Transplantation

Volumn 10, Issue 6, 2012, Pages 592-600

  Hoffmann, Julia ^a   Böhm, Martin ^a   Abele Ohl, Silke ^a   Ramsperger Gleixner, Martina ^a   Spriewald, Bernd M ^a   Zinser, Elisabeth ^b   Steinkasserer, Alexander ^b   Weyand, Michael ^a   Ensminger, Stephan M ^a  

^a Department of Cardiac Surgery ^*  (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Alloantibodies; Chronic rejection; Immunosuppression; Vasculopathy

Indexed keywords

ALLOANTIBODY; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; AORTA GRAFT; ARTERIOSCLEROSIS; ARTICLE; BLOOD ANALYSIS; C57BL 6 MOUSE; CBA MOUSE; CHRONIC GRAFT REJECTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOLOGY; HLA MATCHING; LOW DRUG DOSE; MORPHOMETRICS; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; TRANSPLANT ARTERIOSCLEROSIS;

ANIMALS; ANTIBODY FORMATION; AORTA; AORTA, ABDOMINAL; ARTERIOSCLEROSIS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; SPLEEN; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871275555     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2012.0044     Document Type: Article

References (41)

1. Hertz MI, Taylor DO, Trulock EP, et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant. 2002;21(9):950-970.
2. Lietz K, Miller LW. Current understanding and management of allograft vasculopathy. Semin Thorac Cardiovasc Surg. 2004;16(4):386-394.
3. Weis M, von Scheidt W. Coronary artery disease in the transplanted heart. Annu Rev Med. 2000;51:81-100.
4. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005;80(suppl 2):S181-S190.
5. Gibson WT, Hayden MR. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann N Y Acad Sci. 2007;1110:209-221.
6. Mehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000;165(5):2374-2381.
7. Räisänen-Sokolowski A, Vuoristo P, Myllärniemi M, Yilmaz S, Kallio E, Häyry P. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol. 1995;3(4):342-351.
8. Shimizu H, Takahashi M, Takeda S, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation. 2004;77(11):1661-1667.
9. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85-118.
10. Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation. 2001;72(1):77-83.
11. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988;10(suppl 3):S490-S494.
12. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother. 1998;42(2):216-222.
13. Warnecke G, Bushell A, Nadig SN, Wood KJ. Regulation of transplant arteriosclerosis by CD25+CD4+ T cells generated to alloantigen in vivo. Transplantation. 2007;83(11):1459-1465.
14. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med. 2010;16(7):809-813.
15. Demirkiran A, Sewgobind VD, van der Weijde J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells. Transplantation. 2009;87(7):1062-1068.
16. Lim DG, Koo SK, Park YH, et al. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation. Transplantation. 2010;89(8):928-936.
17. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 alpha,25- dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol. 2001;167(4):1945-1953.
18. Koulack J, McAlister VC, Giacomantonio CA, Bitter-Suermann H, MacDonald AS, Lee TD. Development of a mouse aortic transplant model of chronic rejection. Microsurgery. 1995;16(2):110-113.
19. Ensminger SM, Billing JS, Morris PJ, Wood KJ. Development of a combined cardiac and aortic transplant model to investigate the development of transplant arteriosclerosis in the mouse. J Heart Lung Transplant. 2000;19(11):1039-1046.
20. Morton DB, Griffiths PH. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet Rec. 1985;116(16):431-436.
21. Löscher W, Ungemach FR, Kroker R. Pharmakotherapie bei Haus- und Nutztieren. 2006;7. Auflage:S. 526.Parey, Berlin Germany.
22. Ensminger SM, Witzke O, Spriewald BM, et al. CD8+ T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation. 2000;69(12):2609-2612.
23. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant. 1999;18(2):143-149.
24. Uehara S, Chase CM, Cornell LD, Madsen JC, Russell PS, Colvin RB. Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transplant. 2007;7(1):57-65.
25. Wehner J, Morrell CN, Reynolds T, Rodriguez ER, Baldwin WM 3rd. Antibody and complement in transplant vasculopathy. Circ Res. 2007;100(2):191-203.
26. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24(5):517-525.
27. Kaczmarek I, Ertl B, Schmauss D, et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant. 2006;25(5):550-556.
28. Yamani MH, Starling RC, Goormastic M, et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation. 2000;69(11):2326-2330.
29. Lemström K, Sihvola R, Bruggeman C, Häyry P, Koskinen P. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation. 1997;95(12):2614-2616.
30. Giral M, Nguyen JM, Daguin P, et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol. 2001;12(8):1758-1763.
31. Bravo FJ, Cardin RD, Bernstein DI. A model of human cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 2007;76(2):104-110.
32. Weigel G, Griesmacher A, Karimi A, Zuckermann AO, Grimm M, Mueller MM. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant. 2002;21(10):1074-1079.
33. Lee J, Kim MS, Kim EY, et al. Mycophenolate mofetil promotes down-regulation of expanded B cells and production of TNF-alpha in an experimental murine model of colitis. Cytokine. 2008;44(1):49-56.
34. Schwarze ML, Houser SL, Muniappan A, et al. Effects of mycophenolate mofetil on cardiac allograft survival and cardiac allograft vasculopathy in miniature swine. Ann Thorac Surg. 2005;80(5):1787-1793.
35. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol. 1994;152(10):5135-5141.
36. Galvani S, Augé N, Calise D, et al. HLA class I antibodies provoke graft arteriosclerosis in human arteries transplanted into SCID/beige mice. Am J Transplant. 2009;9(11):2607-2614.
37. Chow LH, Huh S, Jiang J, Zhong R, Pickering JG. Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Circulation. 1996;94(12):3079-3082.
38. Wise M, Zelenika D, Bemelman F, et al. CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts. Eur J Immunol. 1999;29(1):156-167.
39. Russell PS, Chase CM, Colvin RB. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation. 1997;64(11):1531-1536.
40. Steele DM, Hullett DA, Bechstein WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc. 1993;25(1 Pt 1):754-755.
41. Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant. 2002;21(2):282-285.